Comments
Lupin Limited’s shares rose 3.25 per cent after the company secured an approval from the USFDA for its Abbreviated New Drug Application, allowing the marketing of Loteprednol Etabonate Ophthalmic Suspension-0.2%.
The newly approved generic equivalent serves as an alternative to Bausch & Lomb Inc’s reference listed drug, Alrex Ophthalmic Suspension, 0.2%.
Lupin will manufacture the product at its facility in Pithampur, India. Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is designed for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis. The reference product, RLD Alrex, achieved an estimated annual sales figure of $29.1 million in the U.S. as of October 2023 (IQVIA MAT).
The shares rose 3.25 per cent to ₹1,330.90 at 2.48 pm on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.